Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29097
Title: Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.
Austin Authors: Mooi, Jennifer K ;Chionh, Fiona;Savas, Peter;Da Gama Duarte, Jessica;Chong, Geoffrey ;Brown, Stephen;Wong, Rachel;Price, Timothy J;Wann, Alysson ;Skrinos, Effie;Mariadason, John M ;Tebbutt, Niall C 
Affiliation: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia..
The Queen Elizabeth Hospital, Adelaide, South Australia, Australia..
Monash University, Melbourne, Victoria, Australia..
Eastern Health, Box Hill, Victoria, Australia..
Ballarat Regional Integrated Cancer Centre, Ballarat, Victoria, Australia..
University of Melbourne, Melbourne, Victoria, Australia..
La Trobe University, Melbourne, Victoria, Australia..
Austin Health
Olivia Newton-John Cancer Research Institute
University of Adelaide, Adelaide, South Australia, Australia..
University of Melbourne, Melbourne, Victoria, Australia..
Issue Date: 15-Apr-2021
metadata.dc.date: 2021
Publication information: Clinical cancer research : an official journal of the American Association for Cancer Research 2021; 27(8): 2159-2167
Abstract: To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC). This open-label phase II study enrolled patients with unresectable mCRC with no prior systemic treatment. All patients received bevacizumab 7.5 mg/kg 3-weekly and trebananib 15 mg/kg weekly. The primary endpoint was disease control [stable disease, partial response (PR), or complete response (CR)] at 6 months (DC6m). Secondary endpoints included toxicity, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Exploratory biomarkers in plasma angiogenesis-related proteins, tumor gene expression, and plasma antibodies to tumor antigens were examined. Forty-five patients were enrolled from four Australian sites. DC6m was 63% [95% confidence interval (CI), 47-77]. ORR was 17% (95% CI, 7-32), comprising of seven PRs. Median duration of response was 20 months (range, 10-48 months). Median PFS was 8.4 months and median OS 31.4 months. Grade 1-2 peripheral edema and joint-related symptoms were common. Overall incidence of grade 3-4 adverse events (AE) of any type was 33% (n = 15). Expected AEs of bevacizumab treatment did not appear to be increased by the addition of trebananib. In a first-line mCRC population, the dual antiangiogenic combination, bevacizumab plus trebananib, without chemotherapy, was efficacious with durable responses. The toxicity profile of the combination was manageable and did not exceed that expected with bevacizumab +/- chemotherapy. Exploratory biomarker results raise the hypothesis that the antiangiogenic combination may enable the antitumor immune response in immunotolerant colorectal cancer.
URI: https://ahro.austin.org.au/austinjspui/handle/1/29097
DOI: 10.1158/1078-0432.CCR-20-2714
ORCID: 0000-0002-9392-5816
0000-0001-5999-428X
0000-0003-4289-5204
0000-0002-4926-5689
0000-0001-9536-316X
0000-0002-4188-6149
0000-0003-4006-2380
0000-0001-9123-7684
0000-0003-2613-5168
PubMed URL: 33514526
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/33514526/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.